Kristin Etzkorn, DO
Rheumatology · Murrells Inlet, SCNPI 1265674238
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 693 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by AbbVie at 29.1% of the total.
Across 693 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Novartis$1K
- Amgen$1K
- Johnson & Johnson$971
- GSK$814
- Lilly USA, LLC$509
- plus $3K from 32 others
What the payments were for
- Speaking & faculty fees$370%
- Food & beverage$10,86599%
- Education$551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 200 | $3,187 |
| Novartis | 79 | $1,404 |
| Amgen(2 entities) | 74 | $1,208 |
| Johnson & Johnson | 65 | $971 |
| GSK | 55 | $814 |
| Lilly USA, LLC | 31 | $509 |
| Pfizer | 42 | $439 |
| Supernus Pharmaceuticals, Inc. | 44 | $420 |
| UCB, Inc. | 11 | $244 |
| E.r. Squibb & Sons, L.L.C. | 14 | $231 |
| AstraZeneca(2 entities) | 10 | $171 |
| Medexus Pharma, Inc. | 14 | $156 |
| Mallinckrodt Hospital Products Inc. | 6 | $144 |
| Argenx US, Inc. | 3 | $90 |
| Boehringer Ingelheim | 3 | $89 |
| Eisai Inc. | 4 | $89 |
| Sobi, Inc | 2 | $65 |
| Regeneron Healthcare Solutions, Inc. | 3 | $65 |
| Biogen | 3 | $63 |
| Teva Pharmaceuticals USA, Inc. | 4 | $58 |
| ANI Pharmaceuticals, Inc. | 2 | $56 |
| Mallinckrodt Enterprises LLC | 2 | $51 |
| Aurinia Pharma U.S., Inc. | 2 | $47 |
| Bristol Myers Squibb | 3 | $40 |
| Acorda Therapeutics, Inc | 2 | $37 |
| Grifols USA, LLC | 1 | $36 |
| Genentech USA, Inc. | 2 | $36 |
| Amneal Pharmaceuticals LLC | 2 | $33 |
| Tersera Therapeutics LLC | 1 | $28 |
| Scilex Pharmaceuticals Inc. | 1 | $24 |
| Mylan Institutional Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Nevro Corp. | 1 | $21 |
| Harmony Biosciences LLC | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Sandoz | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$113
How this compares
$10,957 in reported general payments places this provider in the 70th percentile of 123 rheumatology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 94 | $976,608 |
| RinvoqUpadacitinib | 17 | $266,768 |
| Enbrel SureclickEtanercept | 32 | $262,919 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 25 | $187,748 |
| EnbrelEtanercept | 23 | $165,000 |
| XeljanzTofacitinib Citrate | 19 | $110,149 |
| Orencia ClickjectAbatacept | 16 | $88,942 |
| BenlystaBelimumab | 12 | $58,593 |
| Hydroxychloroquine Sulfate | 321 | $15,182 |
| MethotrexateMethotrexate Sodium | 259 | $10,549 |
| Duloxetine Hcl | 239 | $10,013 |
| Leflunomide | 126 | $8,689 |
| Febuxostat | 25 | $4,870 |
| Gabapentin | 208 | $4,710 |
| Celecoxib | 159 | $4,630 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $3,187 | $266,76817 claims |
| AmgenEnbrel | $1,208 | $165,00023 claims |
| PfizerXeljanz | $439 | $110,14919 claims |
| GSKBenlysta | $814 | $58,59312 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $24 | $2,17326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 123 rheumatology providers in South Carolina.
Other rheumatology in Murrells Inlet
- Chrysoula PappaMurrells Inlet$6K
- Colin EdgertonSummerville$3.5M
- Gregory NiemerSummerville$2.9M
- Gary FinkSummerville$2.9M
- Clarence LegertonSummerville$2.9M
- Jennifer MurphySummerville$2.8M
- William EdwardsSummerville$1.3M
- Alan BrownGreenville$947K
- Douglas ConawayMyrtle Beach$500K
- Long Huynh-DucGreenville$278K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.